These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28455847)

  • 1. Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Okihara K; Yorozu A; Saito S; Tanaka N; Koga H; Higashide S; Kikuchi T; Nakano M
    Int J Urol; 2017 Jul; 24(7):518-524. PubMed ID: 28455847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Kikkawa K; Iba A; Kohjimoto Y; Noda Y; Sonomura T; Hara I
    Int J Urol; 2018 Apr; 25(4):366-371. PubMed ID: 29397569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
    Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; ; Michalski JM
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):304-317. PubMed ID: 28463150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: outcome and toxicity.
    Yamada Y; Masui K; Iwata T; Naitoh Y; Yamada K; Miki T; Okihara K
    Brachytherapy; 2015; 14(2):118-23. PubMed ID: 25304650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported health-related quality of life up to three years after the treatment with permanent brachytherapy: Outcome of the large-scale, prospective longitudinal study in Japanese-Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation (J-POPS).
    Koga H; Naito S; Ishiyama H; Yorozu A; Saito S; Kojima S; Higashide S; Kikuchi T; Nakamura K; Dokiya T; Fukushima M;
    Brachytherapy; 2019; 18(6):806-813. PubMed ID: 31378511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS).
    Tanaka N; Yorozu A; Kikuchi T; Higashide S; Kojima S; Ohashi T; Katayama N; Nakamura K; Saito S; Dokiya T; Fukushima M;
    Brachytherapy; 2019; 18(4):484-492. PubMed ID: 31072729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil.
    Pugh TJ; Mahmood U; Swanson DA; Munsell MF; Wang R; Kudchadker RJ; Bruno TL; Frank SJ
    Brachytherapy; 2015; 14(2):160-5. PubMed ID: 25255712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Matsushima M; Kikuchi E; Maeda T; Nakashima J; Sugawara A; Ando T; Mizuno R; Nagata H; Miyajima A; Shigematsu N; Oya M
    J Urol; 2013 Mar; 189(3):1014-8. PubMed ID: 23017516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term potency preservation following brachytherapy for prostate cancer.
    Snyder KM; Stock RG; Buckstein M; Stone NN
    BJU Int; 2012 Jul; 110(2):221-5. PubMed ID: 22734475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erectile function after prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Kurko BS; Lief JH; Allen ZA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):437-47. PubMed ID: 15890585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years.
    Stone NN; Stock RG
    Urology; 2007 Feb; 69(2):338-42. PubMed ID: 17320674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of permanent brachytherapy combined with androgen deprivation therapy in an intermediate-risk prostate cancer group without a Gleason score of 4 + 3: a single Japanese institutional experience.
    Okihara K; Kobayashi K; Iwata T; Naitoh Y; Kamoi K; Kawauchi A; Yamada K; Miki T
    Int J Urol; 2014 Mar; 21(3):271-6. PubMed ID: 24033545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS).
    Saito S; Ito K; Yorozu A; Aoki M; Koga H; Satoh T; Ohashi T; Shigematsu N; Maruo S; Kikuchi T; Kojima S; Dokiya T; Fukushima M; Yamanaka H
    Int J Clin Oncol; 2015 Apr; 20(2):375-85. PubMed ID: 24840041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year potency preservation after iodine-125 prostate brachytherapy.
    Nishimura S; Yorozu A; Ohashi T; Sakayori M; Yagi Y; Nishiyama T; Saito S; Shiraishi Y; Yoshida K; Toya K; Shigematsu N
    Int J Clin Oncol; 2014 Oct; 19(5):940-5. PubMed ID: 24170247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial Comment to Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Enatsu N
    Int J Urol; 2017 Jul; 24(7):524. PubMed ID: 28560809
    [No Abstract]   [Full Text] [Related]  

  • 16. Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy.
    Whaley JT; Levy LB; Swanson DA; Pugh TJ; Kudchadker RJ; Bruno TL; Frank SJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e765-71. PubMed ID: 22300559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
    Matsushima M; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Ohashi T; Mikami S; Miyajima A; Shigematsu N; Oya M
    Int J Urol; 2016 Mar; 23(3):247-52. PubMed ID: 26663514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer.
    Okaneya T; Nishizawa S; Nakayama T; Kamigaito T; Hashida I; Hosaka N
    Int J Urol; 2007 Jul; 14(7):602-6. PubMed ID: 17645602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Changes in Health-related Quality of Life After
    Ogasawara N; Nakiri M; Kurose H; Ueda K; Chikui K; Nishihara K; Matsuo M; Suekane S; Murotani K; Muraki K; Hattori C; Ogo E; Igawa T; Ishitake T
    Anticancer Res; 2020 Nov; 40(11):6443-6456. PubMed ID: 33109583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between sexual function and prostate-specific antigen bounce after iodine-125 permanent implant brachytherapy for localized prostate cancer.
    Nishihara K; Nakiri M; Chikui K; Suekane S; Matsuoka K; Hattori C; Ogo E; Abe T; Matsumoto Y; Ishitake T
    Int J Urol; 2014 Jul; 21(7):658-63. PubMed ID: 24650159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.